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Aptamers for Targeted Delivery: 
Current Challenges and Future 
Opportunities
Chetan Chandola and Muniasamy Neerathilingam
Abstract
Aptamers are synthetic ssDNA/RNA molecules that are emerging as novel tools 
for the development of therapeutics, especially for targeted delivery. Aptamers 
are comparable to monoclonal antibodies, which are well-established therapeutic 
molecules, in terms of specificity and affinity to their target. The advantage of 
aptamers over antibodies includes their high stability, ease of synthesis, less batch-
to-batch variation, easy chemical modifications that allow different conjugation 
chemistries, small size for better tissue penetration and low immunogenicity. These 
advantages make aptamers an important tool for use in therapeutics for targeted 
delivery. However, aptamers do have some limitations that have hindered their 
widespread clinical use as a therapeutic agent. Some of their common limitations 
include serum stability, renal filtration and endocytic escape. Other limitations 
that are more specific to aptamers include lack of diversity in the aptamer library, 
nuclease susceptibility and claims of aptamer specificity as well. This book chap-
ter sheds light on these challenges, and using examples, it explains the scientific 
advancements that have been achieved in overcoming these limitations. We will end 
this chapter by discussing the use of high-throughput technology, which is the only 
way of truly industrializing the aptamer technology akin to the development of 
small molecule drugs.
Keywords: aptamers, SELEX, targeted delivery, serum stability, endosomal escape, 
renal clearance, high-throughput
1. Introduction
Aptamers are small single-stranded RNA or DNA oligonucleotides that specifi-
cally bind to their target due to their unique 3-dimensional structure. They were 
first independently developed by the groups of Gold and Szostak in 1990 [1, 2]. 
Aptamers are selected from a pool of random oligonucleotide library (>1015 random 
sequences) by iterative rounds of selection and amplification by a process called 
Systematic Evolution of Ligands by EXponential Enrichment (SELEX). Different 
intermolecular interactions facilitate the interaction of aptamers with their target 
including van der Waal’s forces, electrostatic interactions between charged groups, 
three-dimensional shape, stacking and hydrogen bonds.
Functionally aptamers are same as antibodies; however, their advantages over 
antibodies include small size, less immunogenicity, ease of synthesis, easy chemical 
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modification that allows conjugation with a variety of molecules and stability at 
a higher temperature. Aptamer is comparably smaller (~3 nm) than an antibody 
(10–15 nm) [3], thus, allowing higher penetration in tissues and the ability to bind 
more dense cellular epitopes in living cells. Unlike antibodies, aptamers can be 
selected against non-immunogenic molecules, including proteins or peptides as well 
as toxins. Aptamers have been successfully developed against proteins, peptides, 
dyes, metal ions, viruses, bacteria, toxins, and whole cells. They have high specific-
ity and affinity often comparable with antibodies. Unlike antibodies, they can be 
selected at non-physiological conditions such as extremely high or low tempera-
ture, or pH. Synthetic manufacturing of aptamers allows minimal batch-to-batch 
variation, which is a tedious task to maintain in antibody development. All these 
properties make aptamers as suitable candidates for therapeutic use, particularly 
targeted nano-delivery. Several aptamers have already been selected against cell 
surface targets for targeted delivery of therapeutic payload for different diseases, 
e.g., cancer and human immunodeficiency virus (HIV) infected cells [4]. Table 1 
lists the common differences between antibodies and aptamers.
In this book chapter, we discuss the challenges that hinder the clinical use of 
aptamers as targeted delivery molecules. For example, the small size of aptamers 
is like a double-edged sword. Though it helps in higher tissue penetration, but also 
results in high renal filtration that causes loss of its therapeutic efficiency. Using 
examples we show that how challenges in serum stability, renal filtration, selection 
Antibody (IgG) Aptamer
Size 10–15 nm ~3 nm
Target Only immunogenic targets. Can’t 
be raised against toxic or non-
immunogenic proteins
Produced against immunogenic and non-
immunogenic (e.g., metal ions, dyes, small 
peptides, toxins etc.) targets
Specificity High High
Affinity High High
Penetration Low tissue penetration due to 
large size
High tissue penetration due to small size
Stability (pH, 
Temperature)
Low High
Shelf life Few months (at low temperature; 
repeated freeze-thaw causes 
loss-of function)
Several months (at room temperature) to 
several years (frozen)
Nuclease 
susceptibility
Absent Present (modified nucleotides minimize 
nuclease susceptibility)
Immune response High (except humanized Ab) Absent or low (rare cases)
Batch-to-batch 
variation
Present Absent due to synthetic manufacture
Conjugation Less possibilities Easy conjugation due to chemical nature 
allows functionalization with a wide variety 
of molecules
Synthesis Only in physiological conditions Synthetic
Cost of synthesis High. Requires animal house 
facility or reactors
Low. Synthesized using table-top 
instruments
Scale-of-synthesis Low Scalable
Table 1. 
This table lists the common differences between an antibody (IgG) and an aptamer.
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methodology and endocytic escape have been overcome. We explain the importance 
of proper controls and validation methods in SELEX methodology, which would 
otherwise result in the development of poor quality aptamers and, this might 
ultimately diminish the confidence in this technology. Lastly, we discuss about 
the development of automation in SELEX technology, an important step toward 
industrializing the aptamer selection process.
2. Serum stability
Currently, many aptamers are in different stages of clinical trials for various dis-
eases [5]. Most of the drugs are administered systemically, i.e., intravenously. This 
method poses a challenge of overcoming serum stability, which involves overcom-
ing nuclease activity and coagulation. Here in we discuss these two topics in detail:
2.1 Aggregation
Aptamers have been used to functionalize liposomes to increase their bioavail-
ability through targeted delivery (Figure 1) [4]. Since aptamers are negatively 
charged it is easier to pack them with cationic liposomes. However, serum proteins 
being charged molecules bind to cationic lipids, thus, lowering their targeting 
efficiency due to change in structure, aggregation or dissociation of the aptamer-
cationic lipid complex [6, 7–9]. Polycationic lipids have also shown cyto(toxic) 
effects [10]. The problem of aggregation incurred by the charge of cationic lipids 
can be overcome by using neutral helper lipids [11, 12]. But another challenge is that 
lipid conjugated aptamers may also bind to erythrocytes, and filtered out through 
liver and spleen. For example, 1,2-dioleoyl phosphatidylethanolamine (DOPE), a 
neutral helper lipid, binds to erythrocytes. As an alternative, another neutral helper 
lipid, cholesterol, may be used which shows significantly lower binding to erythro-
cytes as compared to DOPE [10, 13].
Cholesterol conjugated RNA aptamer against Hepatitis C virus (HCV) NS5B 
protein has been used to inhibit HCV replication in human liver cells without 
induction of cytotoxicity in vitro. Next, in this study, the same molecule was 
injected in a mouse model but found no induction of innate immunity. The 
half-life of the cholesterol-conjugated aptamer was longer than that of the 
Figure 1. 
Illustration showing (a) non-functionalized liposome and (b) aptamer-functionalized liposome carrying drug 
molecules.
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non-cholesterol-conjugated aptamer, and in accordance, cholesterol conjugation 
reduced the clearance by 9-fold [14].
It is important to note that no one lipid composition induces cytotoxicity in all 
cell types, i.e., a conjugated lipid may be toxic to one cell type but not to another. 
Improvements of lipid formulations are constantly explored by the addition of 
different lipids, targeting molecules, or shielding moieties designed to prevent 
clearance in vivo. Use of neutral lipids for aptamer administration has been explored 
less due to the difficulty in loading hydrophilic aptamer molecules in the neutral 
lipids for formulation, as compared to (poly)cationic lipids. Liposomes are just 
one tool for enhancing the efficacy of aptamers for targeted delivery, and there are 
multitudes of vehicles that are being examined.
2.2 Nuclease activity
Nuclease activity of the serum is helpful in cleaving foreign DNA, thus, it is 
a way of prevention from pathogens. However, this activity is deleterious to the 
oligonucleotide-based therapeutics, including aptamers. Unmodified aptamers may 
have very short half-lives in vivo (<10 minutes) [15]. Two types of nucleases act on 
these aptamers, viz., exonucleases and endonucleases. Hence, different strategies 
have been designed to prevent the cleavage activity of each of the nucleases.
In-SELEX and post-SELEX strategies can be utilized to develop nuclease resis-
tant aptamers. Each of these two strategies has its own advantage and limitation. 
We discuss these two below:
2.2.1 In-SELEX
In this methodology aptamers with the desired modification are generated 
during the aptamer selection process using modified nucleotides, e.g., modified 
2′ sugar position using 2′-amino pyrimidine nucleosides [16, 17], 2′-fluoropyrimi-
dine nucleosides [18, 19], 2′-O-methyl purine [20], and 2′-O-methyl pyrimidine 
nucleosides [21, 22] and locked nucleic acids (LNAs) [23, 24] have been commonly 
used for this purpose, preventing resistance from endonucleases. Macugen, the 
only FDA approved therapeutic aptamer, was also selected using this approach 
[25]. The Advantage of this methodology is that no further modification is required 
in the selected aptamers, thus, ruling out the possibility of loss of function due to 
post-SELEX modification. However, use of unnatural nucleotides posed a challenge 
to early researchers since wild-type DNA/RNA polymerases could not amplify the 
unnatural aptamers during preparative PCR round of aptamer selection. However, 
using synthetic biology researchers developed new polymerases that could amplify 
oligos with unnatural nucleotides. Still, amplification using these mutant polymer-
ases is not comparable with natural polymerases; hence, aptamer library amplifica-
tion is a bit challenging.
SOMAmers are another class of aptamers that bear dU residues at the 5′-posi-
tion. These are uniformly functionalized at the 5′-position with various moieties 
(e.g., benzyl, 2-naphthyl, or 3-indolyl-carboxamide). These moieties can interact 
with the target molecule and form novel secondary and tertiary structural motifs 
within the SOMAmer. Introduction of dU at the 5′-position offers nuclease resis-
tance to these molecules [26].
2.2.2 Post-SELEX
Post-SELEX involves the introduction of desired modification in pre-selected 
aptamers during solid-phase chemical synthesis. This method may often lead 
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to reduced affinity or specificity of the aptamers due to the structural change in 
the aptamer that is brought upon by the modification. Hence, a combination of 
methods has to be tested on the aptamer, and one that renders no loss of function 
has to be selected. Modification of 5′ and 3′ nucleotides is most common and 
effective in this case. Sometimes unmodified aptamers may demonstrate high 
resistance to serum nuclease activity [27]. This feature might develop due to the 
unique 3-D conformation of the aptamer that protects the 5′- and 3′-termini from 
exonucleases.
Spiegelmers are excellent nuclease resistant L-form RNA or DNA aptamers that 
are chiral inversions of the natural D-forms. Since naturally occurring nucleases can 
act only on D-form of nucleotides, they are very less likely to degrade the L-form 
spiegelmers [28]. Also, due to their unnatural conformation, they are less likely to 
generate an immune response. The unnatural conformation of spiegelmers also 
renders it unfit for processing by polymerases for amplification during SELEX 
process. Hence, in the first step, an aptamer library of natural D-oligonucleotides is 
selected against a synthetic enantiomer of the L-protein target. After the aptamer 
selection is done, aptamers are converted from D-form to L-form. As per the rules 
of symmetry, the resulting L-aptamers (spiegelmers) would bind to the natural 
D-protein target with the same affinity as the D-aptamers bind to the mirror image 
selection target [29].
3. Diversity of aptamer library
As we know, aptamer binding to its target depends on its 3-dimensional confor-
mation, which is ultimately governed by its sequence. Hence, an aptamer library 
with a high degree of sequence variability will have a high variety of structurally 
variant aptamers; therefore, such a library will have a higher degree of success in 
developing tight binding aptamers to its target. In contrast to proteins, which are 
made of 20 different amino acids due to a variety of functional groups, nucleic acids 
possess a very limited variety of functional groups, i.e., only four bases (adenine, 
guanine, cytosine and thymine/uracil). Thus, aptamers can be endowed with 
protein-like properties by addition of functional groups that mimic amino acid 
side-chains to expand their chemical diversity [26].
SomaLogic, a leading company in aptamer development, pioneered in increas-
ing the repertoire of aptamer sequences in a library. They introduced new func-
tional groups, i.e., hydrophobic side chains (e.g., naphthyl, benzyl, tryptamino 
and isobutyl) at 5′-position of dUTP nucleotide. Aptamers developed using these 
modified nucleotides were called Slow Off-rate Modified Aptamers (SOMAmers), 
and they showed higher success rate in aptamer selection against difficult pro-
teins with success rate going from <30% for unmodified aptamers to >90% for 
SOMAmers [30].
Kimoto et al. used an extra base pair Ds:Px in the initial library to introduce 
variety, and developed aptamers with 100-fold higher affinity as compared to the 
unmodified analogs against VEGF-165 (vascular endothelial growth factor) [31]. 
Sefah et al. developed introduced non-natural nucleosides Z and P to develop 
aptamers specifically targeting liver cancer cells [32]. In another work, glycosyl-
ated aptamers were used in a method called SELection with Modified Aptamers 
(SELMA) to develop low-nanomolar affinity aptamers against HIV broadly neutral-
izing antibody 2G12 [33]. These antibodies protect against HIV by recognizing the 
unique carbohydrate epitope on HIV. Here, the glycosylated aptamers worked as 
a scaffold that presented carbohydrate in a manner that mimics their multivalent 
presentation on HIV, thus it could be used as a vaccine component.
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4. Renal filtration
Renal filtration of small molecule drugs is a phenomenon that needs to be over-
come for efficient therapeutic use. Owing to their small size, aptamers also undergo 
this challenge. An aptamer of 6–30 kDa mass has a size of <5 nm [34]. When an 
unmodified aptamer is administered intravenously, even using stabilizing backbone 
modifications, they are subjected to rapid excretion through renal filtration, hence, 
reduced circulation time. To overcome this challenge, aptamers are functionalized 
with bulky moieties viz., polyethylene glycol (PEG), liposomes, proteins, choles-
terol, organic or inorganic nanomaterials, or multimerized to reach a mass above 
the threshold of glomerulus cut-off (30–50 kDa) [34].
4.1 PEG attachment
PEGylation is one of the most common methods to prevent renal filtration of 
aptamers. PEG is a flexible, uncharged and a highly hydrophilic polymer that is widely 
conjugated with therapeutic drugs to reduce reticuloendothelial clearance, extend 
circulation time and improve drug efficiency [35]. Macugen, which is the only FDA 
approved aptamer drug in the market is also PEGylated. PEG decreases aggregation 
and increases the solubility of the conjugates. PEGylation of Macugen increased its 
half-life to 9.5 –12.5 hours after intravenous and subcutaneous injection, respectively, 
in the plasma, and up to 94 hours in vitreous humor [36, 37]. Similarly, PEGylation 
also increased in vivo half-life of M7, a DNA aptamer, from <1 to 24–48 hours [38]. 
This modification did not cause any change in the specificity of M7 aptamer toward 
its target PD-1 (Programmed death protein 1) and suppressed the growth of PD-L1 
(Programmed death-ligand 1) positive colon cancer carcinoma in vivo [39].
4.2 Cholesterol
A 29 nucleotide-log 2′-F pyrimidine modified RNA aptamer was reported to 
inhibit Hepatitis C virus (HCV) replication in vitro. In the follow-up study, this 
aptamer was derivatized with cholesterol to form cholesterol aptamer conjugate 
(chol-aptamer). This conjugate entered the cell and inhibited HCV RNA replication 
in a cell-based system successfully. Systemic administration of chol-aptamer was 
well tolerated by mice and increased retention time in plasma [14].
4.3 Dialkyl lipids
Willis et al. conjugated diacylglycerol (DAG) to the 5′-end of a nuclease resistant 
VEGF aptamer [40]. This DAG-aptamer conjugate was then incorporated to a lipo-
some bilayer, which resulted in aptamers with improved anti-VEGF activity in vitro 
and in vivo, both. Importantly, this DAG-aptamer-liposome complex had a consid-
erably better residence time in plasma as compared to unmodified aptamer [40].
5. Toxicity
Toxicity, side effects, and immunogenicity are one of the most important criteria 
in drug evaluation, apart from shelf life and efficacy of the drug. Aptamers have a 
significant advantage over antibodies due to their minimal or non-immunogenic 
nature. Early preclinical studies using Pegaptanib sodium (Macugen), the aptamer 
drug for preventing wet age related macular degeneration (AMD), did not exhibit 
any intrinsic toxicity during preclinical studies [37, 41, 42]. The only side effect 
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reported arose almost exclusively due to the injection procedure instead of the drug 
itself [43]. Similarly, other works have also described aptamers as non-toxic thera-
peutic agents [44, 45].
Though aptamers may be inherently non-immunogenic, chemical modifica-
tion or conjugation may render them immunogenic or cytotoxic. Hence, chemical 
modification of aptamers works as a double-edged sword. For example, LNA-
modified nucleic acids have shown severe hepatotoxicity [46]. 2′-fluoro pyrimidine 
and 2′-orthomethyl pyrimidine modifications are commonly used in aptamers to 
introduce endonuclease resistance. 2′-fluoropyrimidine modified RNA aptamers 
lead to cytotoxicity and induction of interferon-beta expression in human cancer 
cells in vitro. Interestingly, 2′-orthomethyl pyrimidine completely abrogated the 
induction of cell death and cytokine expression in the same cells [47].
There is a limited toxicological data available on aptamers. Mainly because the 
field is still in its initial stage and the majority of aptamer-based drugs are still 
under clinical trials. In comparison, a significant amount of toxicological data is 
available for antisense oligonucleotides (ASOs). Some cues might be taken from 
toxicity studies on ASOs; however, we must remember that aptamers are structur-
ally a different class of oligonucleotides; hence, they may not behave in exactly the 
same way as ASOs. Toxicological properties of ASOs have been described in earlier 
reviews [48–50]. Less information is available on other class of immunostimulatory 
oligonucleotides viz., siRNA, gene therapy, and other partially or completely nucleic 
acid-based molecules. Three major oligonucleotide-based class effects that have 
been described are: polyanionic effect, the stimulation of innate immunity, and 
tissue accumulation of oligonucleotide material [51]. These class effects are briefly 
described below.
Polyanionic effects occur due to the non-specific off-target interaction with 
proteins that may affect protein function and it usually occurs at a high concentra-
tion of ASOs. The toxicological effects of polyanionic effect include activation of 
the alternative pathway of complement (C′) that results in pseudohypersensitivity 
responses and inhibition of the coagulation pathway, thus, resulting in delayed 
clotting. Complement activation has been studied predominantly in non-human 
primates, and to some extent in humans. Complement activation is a threshold-
dependent phenomenon and will occur acutely once the threshold is crossed [52].
Stimulation of innate immunity has been reported for ASOs. This activation 
occurs due to the interaction of Toll-Like Receptor 9 (TLR 9) with the CpG motif 
within the single-stranded DNA. When CpG motifs are unmethylated, they act 
as immunostimulants [53]. Unmethylated CpG motifs are common in microbial 
genomes but occur quite less in vertebrate genome, hence they are called as 
pathogen-associated molecular patterns (PAMPs) [54]. CpG PAMP is recognized by 
pattern recognition receptor TLR9, which is expressed constitutively by B cells and 
plasmacytoid dendritic cells (pDCs) in humans and other higher primates [55].
Lastly, oligonucleotide accumulation is observed in certain tissues and cells. 
This accumulated material is termed basophilic granulation, and it is observed 
most commonly in renal proximal tubular epithelium and tissue macrophages. 
Accumulation of basophilic granules usually has no effect on associated cells; how-
ever, its accumulation at a very high level in cells, especially renal proximal tubular 
epithelium, may lead to cytotoxicity and eventually organ dysfunction [56].
Apart from the above mentioned three oligonucleotide class effects, there are 
other effects that should also be studied; however, these three are the most com-
monly observed and, hence, should be assessed carefully. In a very interesting work, 
Guo et al. demonstrated that RNA molecules of different shape, size or sequence 
can initiate immunogenicity at different levels in vitro and in vivo, both. Findings 
from this work suggest that properties of RNA nanoparticles may be tuned for safe 
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use as therapeutic nanocarriers [57]. Findings from this work may be extrapolated 
to RNA aptamers to some extent.
Conjugated moiety may also cause an adverse affect in aptamer drug. For 
example, penivacogin, a PEGylated aptamer drug, induced severe allergic reac-
tion during first exposure to the drug during phase III clinical trials. The allergy 
occurred due to pre-existing anti-PEG antibodies [58]. PEG is widely used in 
several consumer products including topical and parenteral medications. Possibly, 
exposure to these wide varieties of products leads to the development of anti-PEG 
antibodies [35].
Although less clinical data is available to assess the cytotoxicity of aptamers, 
studies in animal models show low or no cardiotoxicity, hepatotoxicity or renal 
toxicity. Doxorubicin (DOX), a widely used anticancer drug causes cardiotoxicity 
as a side-effect due to non-specific uptake. Neither liposomal DOX nor PEGylated 
DOX has resolved this issue. However, aptamer-DOX conjugate is known to reduce 
this cardiotoxicity along with increase in efficacy toward tumor suppression in 
comparison to non-targeted delivery [59] in vivo.
The hepatic uptake of aptamer functionalized gold nanostars (Apt-Au NS) 
was studied by Dam et al. They found high accumulation of the complex in liver; 
however, there was no hepatic acute toxicity. This was probably due to the high 
accumulation of the complex in macrophages instead of the hepatocytes [60]. 
Similarly, other works also demonstrated lack of hepatic and renal toxicity in vivo 
for aptamer-mediated tumor suppression [45, 61].
6. Selection process
Aptamers are selected from a pool of random single-stranded DNA/RNA 
oligonucleotide library (>1015 random sequences) by iterative rounds of selection 
and amplification by SELEX method as shown in Figure 2 [4]. Therapeutic aptam-
ers have been developed against cell surface targets [62] as well as for delivery of 
therapeutic conjugates into the cells, i.e., for internalization [3]. Though the selec-
tion method is fundamentally the same for developing aptamers for either use, the 
cell-internalizing aptamers require more points to be addressed to ensure a higher 
degree of success. Endosomal escape and effective delivery to the cytosol is an 
important aspect that should be considered for the effective biological activity of 
a cargo. Here we describe current selection methods commonly used for selection 
of cell-internalizing aptamers, and discuss the limitations of each method. For 
this purpose, here we compare the two commonly used strategies, i.e., SELEX and 
cell-SELEX.
6.1 SELEX
Aptamers have been historically selected against cell surface biomarkers using 
purified or recombinant proteins. Majority of aptamer therapeutics that are cur-
rently in clinical trials have been selected using this methodology. However, there 
are problems associated with this selection method since the protein against which 
selection is done might not be in its natural conformation. Proteins are present in 
physiological milieu in a unique 3D conformation due to either posttranslational 
modification or their association with other interacting proteins. Proteins that 
are produced in vitro usually don’t possess these post-translational modifications, 
specifically, if they produced in a prokaryotic system, e.g., commonly used E. coli. 
Hence, it is advisable to use eukaryotic expression system viz., mammalian, yeast 
or insect cells as they would possess post-translational modifications which may 
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be crucial for the correct 3D conformation for selection of aptamers. However, low 
protein yield might be an issue if we chose a eukaryotic expression system over the 
prokaryotic one. There is also a possibility that recombinant cell surface proteins 
may be insoluble since they need interaction with other cell components (e.g., 
G-protein coupled receptor), or form multimeric and/or multivalent structures 
[63, 46]. Lastly, in the majority of cases, aptamer selection is done using only the 
extracellular domain of the target protein to avoid aptamer selection against the 
intracellular region of the protein; however, the absence of transmembrane domain 
may again alter the natural conformation of the protein. Therefore, there is a pos-
sibility that aptamers selected using protein-based SELEX approach might not be 
able to bind their target in a physiological milieu. Liu et al. selected RNA aptamers 
against histidine-tagged epidermal growth factor receptor variant III (EGFRvIII) 
ectodomain. This receptor is present in glioblastoma, but not in normal brain 
tissue. This protein was expressed in an E. coli expression system, hence, lacked a 
specific post-translational modification, i.e., glycosylation. Lack of glycosylation at 
this particular site resulted in significant alteration of EGFRvIII protein structure 
and, hence, the selected aptamer was unable to bind this receptor protein in target 
cells [64]. Using recombinant protein with a tag-normally used for affinity column 
based purification of a recombinant protein, e.g., His tag-may result in non-specific 
aptamer selection against the protein tag; hence, it is always recommended to cleave 
the tag before a purified recombinant protein is used for aptamer selection. Lastly, 
attachment of a protein to the matrix may result in non-specific aptamer selection 
against the matrix itself.
Figure 2. 
Diagrammatic representation of the systematic evolution of ligands by EXponential enrichment (SELEX) 
method. A library of ~1015 different single-stranded DNA/RNA molecules is incubated with the target 
molecules followed by washing. Unbound sequences (non-specific aptamers) are discarded. Bound sequences 
are recovered and added to the negative control target. Here, the bound sequences (these are aptamers binding 
to common epitopes) are discarded, and the unbound sequences (target-specific aptamers) are recovered. These 
sequences are amplified and subjected to further rounds of in vitro selection followed by sequencing after the 
final selection round. The figure is adapted from Chandola et al. [4].
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6.2 Cell SELEX
Above mentioned limitations, viz., altered 3D conformation, undesired aptamer 
selection against the protein-tag or matrix can be overcome by using cell-SELEX 
methodology. In cell-SELEX aptamer selection is performed on live cells in vitro, 
hence, target surface proteins are present in their native conformation. Unlike 
protein-based SELEX, cell-SELEX does not need any prior information about the 
native conformation or biological function of the target protein. This method relies 
on the difference in the expression pattern of cell surface receptors between the dis-
eased target cells (e.g., cancer cells) and the non-diseased cells (e.g., healthy cells). 
The aptamer selection is first performed on a negative control, i.e., healthy cells. 
From here, the unbound aptamers are collected and added to the test cell line, i.e., 
diseased cells. Only the unbound aptamers are collected from negative control cells 
because they are uncommon among the target and control cells, and it possibly has a 
set of aptamers that bind the upregulated cell surface receptors that are present only 
on target diseased cells. Using the above-mentioned methodology, cell-SELEX has 
been used to identify novel tumor biomarkers [65]. In our experience, major chal-
lenge of cell-SELEX is the optimization of aptamer enrichment by PCR as compared 
to protein-based SELEX. This is due to the inhibitors or other cellular contaminants 
(e.g., DNA or RNA) that come in the aptamer pool which inhibit the polymerase-
based PCR reaction for enriching aptamer pool during each round of selection. Also, 
lack of prior knowledge about the identity and expression level of the biomarker may 
lead to aptamer selection against unrelated/unwanted off-target surface molecules 
that are co-expressed on target cells; hence, more rounds of counter selection with 
the control cell line is required to improve the selectivity of aptamers.
An ideal aptamer candidate for internalization purpose should bind to a cell 
surface receptor that is present in high quantity, and it should have a high rate of 
endocytosis upon binding of a ligand. However, aptamers selected by cell-SELEX may 
not fall in this category always. Hence, researchers have developed novel strategies 
to facilitate enrichment of cell internalizing aptamers by alteration of the traditional 
cell-SELEX protocol. For this purpose, Thiel et al. developed a methodology called 
cell-internalization SELEX. Here, target cells were incubated with an RNA library fol-
lowed by high-salt wash [66]. This method eliminates the non-internalizing surface 
bound aptamers or those that internalize at a slower rate. Cell internalizing aptamer 
against Human epidermal growth factor receptor (HER2), a transmembrane protein 
overexpressed in breast cancer cells was selected using this method [66]. Later studies 
reported that a high-salt wash is insufficient to remove the non-internalizing surface 
bound aptamers. Hence, Levy et al. (2012) used a cocktail of RNAses to digest the cell 
surface bound non-internalizing aptamers [67, 68]. Using this strategy, this group 
selected cell internalizing 2′-fluoropyrimidine RNA aptamer called c2 against human 
transferrin receptor (hTfR).
Proteinase K is a broad-spectrum serine protease that cleaves peptide bond 
adjacent to the carboxyl group of aliphatic and aromatic amino acids with blocked 
alpha-amino groups. Proteinase K was used as an alternate approach to digest 
protein domains present on the cell surface after incubation with aptamer library. 
Thus, digestion of protein domains would render loss of cognate epitopes needed 
for aptamer binding. After proteinase K treatment and washing of the cells, the 
aptamers non-specifically bound to the cell surface proteins would be removed, and 
only those which have internalized the cells can be obtained, as desired. Proteinase 
K treatment can be used for DNA and RNA aptamers both, unlike RNase treatment 
used by Levy et al. [68] which is applicable only for RNA aptamers. Iaboni et al. 
used this method to select cell-internalizing aptamers against insulin receptors on 
human glioma cells [69].
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7. Strategies for endosomal escape of cargoes
The therapeutic efficiency of a cell-internalizing platform depends on its ability 
to escape from endosomes and deliver the therapeutic cargo to the cytoplasm. The 
efficiency of endosomal escape, which is 0.01% for traditional delivery systems, 
should be increased significantly to achieve higher therapeutic efficacy [70]. 
Two types of strategies are commonly employed to facilitate endosomal escape. 
First method uses endosomal destabilizing agents that alter the permeability of 
endosomal membranes, e.g., chloroquine. However, the limitation of this method 
is that these endosomolytic agents may reach lysosomes, thus, lysing them and 
lead to cytotoxicity due to the release of lysosomal lytic enzymes. Second method, 
which is found to be non-toxic in several studies, uses engineered viral or bacterial 
cell penetrating peptides (CPPs) (e.g., truncated HIV-1 TAT peptide or Aurein1,2) 
[71–73]. However, CPPs can increase the escape of cargoes from endosomes to the 
cytoplasm by only 5- to 8-fold, which is not enough to generate an effective plat-
form for clinical applications [70]. Below we will discuss the strategies that could 
be used with aptamers to enhance their endosomal escape properties or that of the 
attached cargo.
Any targeted delivery platform for internalization of a cargo to cells is endo-
cytosed by receptor-mediated endocytosis (RME) to a large extent [74], and 
aptamers fall in this category. The endocytosed cargo first reaches early endosomes, 
from where it is either sent back to cell surface (recycling endosomes) or sent to 
late endosomes, and finally lysosomes. The cargo may be degraded by hydrolytic 
enzymes in lysosomes. Therefore, if a cargo enters an endosome that is destined for 
lysosomes, it has a short period of time within which it has to escape to the cytosol 
to prevent its degradation. Different strategies have been developed that can be 
used in conjugation with aptamers, which may help in their endosomal escape. 
Endosomal sorting complex required for transport-I (ESCRT-I) is a protein complex 
that plays an important role in maturation and trafficking of endosomal cargoes. 
Wagenaar et al. silenced two components of ESCRT-1 (i.e., TSG101 and VPS28) to 
induce endosomal escape of delivered anti-miRNA in vitro and in vivo, both, and 
resulted in tumor regression [75].
Nieman-Pick type C1 (NPC1) is a late endosomal/lysosomal membrane protein 
required for extracellular recycling of endosomal contents. A small molecule 
inhibitor of NPC1 protein, termed NP3.47, was earlier used to delay maturation of 
non-recycling endosomes [76]. The Study found that NP3.47 caused 3-fold higher 
accumulation of lipid nanoparticle (LNP) formulations of siRNA, i.e., LNP-siRNA 
as compared to the controls in late endosomes/lysosomes in a variety of cell lines 
causing 4-fold higher gene silencing. Authors proposed that trapping LNP-siRNA 
in late endosomes extended the window of time for a more efficient escape into the 
cytosol to facilitate siRNA induced gene silencing [76].
pH-dependent cargo release is also an effective way for endosomal escape. 
Anti-PSMA aptamer-siRNA chimera was conjugated to a pH-dependent polyhisti-
dine domain via dsRNA binding domain (dsRBD). In the acidic compartment of a 
mature endosome (pH ≤ 6), Histidine becomes protonated and facilitates osmotic 
swelling that leads to cargo release into the cytosol, a mechanism known as the 
proton sponge effect [77]. By this mechanism, the polyhistidine tag facilitated the 
escape of anti-PSMA aptamer-siRNA chimera from late endosome to cytosol result-
ing in improved silencing of the target gene [78].
Another straightforward strategy for cytoplasmic delivery is to perform aptamer 
selection against a cell surface target protein that internalizes to other compart-
ments by receptor-mediated endocytosis. RME facilitates more rapid internaliza-
tion of the targeting moiety as compared to untargeted complexes. Depending on 
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the intracellular receptor-dependent or independent trafficking path, the fate of 
targeting moiety can be controlled, e.g., macromolecules internalized by clathrin-
dependent RME are mostly destined for lysosomal degradation whereas clathrin-
independent internalization leads to endosomal accumulation and sorting to a 
non-degradative path [74]. However, this method can be used against those targets 
that have previously been characterized, e.g., nucleolin. Nucleolin is a nuclear 
ribonucleoprotein that is overexpressed in cancer cells where it shuttles among the 
cell-surface, cytoplasm and the nucleus. AS1411 aptamer, a G-quadruplex forming 
oligonucleotide, specifically binds nucleolin and displays antiproliferative activity 
against cancer cells [79]. However, there are conflicting reports regarding nucleolin-
mediated uptake of AS1411 since one study suggest that it is nucleolin dependent 
and the other suggests that it is nucleolin independent. Though the mechanism 
of escape of AS1411 from endosomes to cytoplasm is unclear, it is likely that its 
interaction with nucleolin, which shuttles between different cellular compartments, 
plays a role in it [80].
8. Quality of known aptamers
Aptamers have generated excitement in the scientific community in the last 2 
decades due to their unique characteristics that helped them gain popularity for 
use in therapeutic purposes. They have been used as both agonists and antagonists 
targeting cell surface receptors [34]. The Ability of aptamers to specifically bind the 
cell surface targets catapulted them into the field of targeted delivery of therapeu-
tics. They can be easily conjugated with small molecule drugs, liposomes, proteins, 
siRNAs, miRNAs, or other nanoparticles. However, when industry leaders in the 
field of siRNA/miRNA delivery tried to recapitulate the results of siRNA delivery, 
they failed [81]. Also, since the approval of Macugen, in 2004, by Food and Drug 
Administration (FDA), no other aptamer-based drug has made to the market. 
Failure of Fovista (anti-PDGF aptamer to prevent age-related macular degenera-
tion) and Reg1 (an antifactor IXa aptamer paired with its complementary reversal 
agent, reverseran, to restore blood clotting) failed in phase III clinical trials due to 
no improvement over current standard care methods has also been disappointing 
[81]. However, Reg1 also resulted in serious allergies in patients, albeit it was due 
to conjugated PEG, and not due to the aptamer itself. Though failure of drugs in 
clinical trials is quite common as many more drugs fail during trials than pass them, 
but more disappointingly, there is a lack of aptamer-based drugs that are even 
advancing to the clinic [5]. Unlike antibodies and antibody-based drugs which are 
supported by big pharmaceutical companies, aptamer development has been largely 
relegated to academic labs that are often, comparatively, poorly funded.
Levy group observed lack of reproducibility in aptamer binding to its target or 
therapeutic effects in several cases [81]. This unreliability among novel molecules is 
a bad precedent that may generate a lack of confidence in an upcoming technology. 
The poor reproducibility, or robustness, of these aptamers might be due to poor 
downstream characterizations, which is, in fact, very important for validation of 
novel aptamers. There is also no standard way of assessing aptamer binding results, 
as different labs use a variety of methods to assess the binding function of their 
selected molecules. Hence, there is no straightforward way to compare or validate 
results between different labs. Other labs often cite the work from previous labs 
without revalidating the aptamer that they intend to use. Lack of funds, resources 
or time are often the reason nor not revalidating the aptamers for their own pur-
poses; however, if the aptamer field has to grow, a bit more care and diligence will 
be needed from the labs that are developing aptamers as well as the end user.
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Here, we briefly discuss the validations and controls that should be used to 
ensure a more reliable selection of aptamers for targeted delivery. Soluble proteins 
or peptides are often used as targets for aptamer selection, and their binding affin-
ity or specificity is confirmed by binding assays. However, further validation using 
a negative control cell line or a knockout cell line is quite important for such aptam-
ers since aptamers may be selected against an epitope that is buried in the plasma 
membrane or it might be located in the cytoplasmic region.
Varieties of assays are performed to study aptamer binding to target cells, 
e.g., radioactively or fluorescently labeled aptamers. However, limitation of these 
assays is that they are performed on bulk cells, hence, it is not known whether the 
observed signal is due to interaction with the entire cell population, or only a subset 
of cells. Confocal imaging is often used as a qualitative method to confirm internal-
ization of aptamers, or localization in a particular organelle. Quantification of the 
signal and statistical methods are often not performed. Since a very small number 
of cells are typically interrogated, statistical analysis is not performed [81]. The low 
throughput of imaging, i.e., low cell counting in confocal imaging is usually due 
to strong lasers that may bleach the fluorescent labeled aptamers. However, with 
the advent of LED-based high content imaging systems, quantitative analysis in a 
high-throughput fashion can be easily performed. It is recommended that aptamers 
should be conjugated to high-quality fluorophores in these studies, i.e., Alexa Fluor 
dyes or quantum dots instead of traditionally used FITC or TRITC, as these are less 
resistant to photobleaching. Flow cytometry is also highly recommended to study 
aptamer internalization due to its high sensitivity, and its ability to interrogate each 
cell in a population individually.
It is advisable to limit the incubation time with aptamers during cell-internaliza-
tion SELEX, typically up to ~1 hour. Incubation with cells for an extended period of 
time may lead to significant levels of non-specific uptake. It is also recommended 
to use blocking agents to prevent non-specific binding of aptamers to cell surface. 
Aptamers are polyanions, therefore, they can readily interact with cell surface moi-
eties due to charge-charge interactions, especially at high concentrations (>1 μM). 
A Nonspecific polyanionic competitor like ssDNA or tRNA can be used successfully 
to significantly inhibit non-specific aptamer binding to cells [81]. As an alternative, 
dextran sulfate may also be used for the same purpose [5].
9. Automation of SELEX protocol
Aptamer selection is a repetitive, time-consuming and a laborious process. The 
immense number of PCR reactions during preparative PCR step for the enrichment 
of selected aptamers is also a monotonous process which might lead to manual 
errors. Various tasks in molecular biology such as DNA sequencing, plasmid prepa-
ration, and microarray construction have been automated [82, 83]. The automation 
of these processes has substantially increased the throughput of sample preparation 
or assays and significantly reduced the amount of time a researcher must spend to 
perform purely repetitive mechanical tasks.
Automation reduces variability during the selection process, leading to better 
reproducibility of results. Depending on the degree of automation, manpower, 
time and consumables can be reduced, whereas throughput can be increased by 
parallelization. The extent of lab automation depends on scope and timeline of 
the project, and the allocated budget [84]. In principle, there are two concepts of 
automation, viz., full automation and unit-automation. A full automation pipeline 
is the one where all steps of the process or assay are performed without any human 
intervention [85]. In unit automation, human intervention is required in certain 
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stages and only individual stages in a pipeline are partially automated, independent 
of each other [86]. The advantage of unit-automation is that it keeps a highly open 
architecture of the pipeline allowing individual modules to be easily modified or 
exchanged; hence, the pipeline can be easily extended or modified [87].
Unlike the discovery of small molecule-based drugs in industry, where automa-
tion is a norm, development of novel aptamers has happened in individual labs in an 
academic research setting. For truly industrializing the aptamer discovery process, 
it is imperative to develop high-throughput strategies for aptamer development at 
different levels, viz., aptamer selection process, sequencing, and characterization 
of aptamers involving affinity and specificity studies toward its target. Here we 
discuss about the high-throughput technologies which have been developed facili-
tating high-throughput selection of aptamers.
The first attempt to automate aptamer selection process was performed by the 
group of Ellington [82] followed by some other improvements [88–92]. It brought 
down the selection time from weeks or months to days. Automation of the SELEX 
process increased the throughput of selections, but shifted the bottleneck within a 
selection pipeline toward the identification and evaluation side.
In 2011 the group of T.M. Soh developed a Quantitative Parallel Aptamer 
Selection System (QPASS), which integrates microfluidic aptamer selection 
(M-SELEX) and next-generation sequencing (NGS) with in situ synthesized 
aptamer arrays, enabling simultaneous measurement of affinity and specificity of 
several 1000 candidate aptamers in parallel. Major advantage of this high-through-
put platform is that it automated the characterization, i.e., finding the affinity and 
specificity of aptamers which is a major bottleneck in aptamer selection, since tradi-
tionally the affinity and specificity of aptamers is measured individually in a serial 
manner [93]. This group used angiopoietin-2 (Ang2) as a target and performed four 
rounds of M-SELEX followed by next-generation sequencing to obtain enriched 
aptamer sequences. Next, using aptamer arrays they simultaneously measured 
dissociation constant (Kd) of ∼1000 aptamer candidates in parallel, identifying six 
high-affinity Ang2 aptamers with Kd <30 nM.
Development of NGS platform in the last decade has revolutionized the aptamer 
selection process. The Schroeder group in 2010 made the initial attempt in this 
direction as they combined genomic SELEX with high-throughput sequencing 
for the identification of genomic aptamers [94]. The same year, Soh group (2010) 
integrated microfluidic SELEX with high-throughput sequencing to obtain novel 
aptamers against platelet-derived growth factor BB (PDGF-BB) protein in just three 
rounds of selection, which traditionally takes 12–20 rounds [95]. Advantage of HTS 
is that it can track the copy number and enrichment fold of more than 10 million 
individual aptamer sequences through multiple rounds of selection. This enables 
the identification of high-affinity aptamers without the need of fully converging 
the aptamer pool to a small number of sequences, which is required for cloning-
based selection method. Similarly, Hoon et al. obtained high-affinity aptamers after 
just one round of positive selection followed by HTS [96].
10. Conclusion
Since the inception of aptamer technology, this field has significantly evolved 
with its foray into a wide variety of applications, including targeted delivery. 
Aptamers caught the attention of researchers due to their unique advantages for use 
in therapeutics in nanomedicine due to their small size that gives higher penetration 
in tissues as compared to antibodies, ease of synthesis, high specificity and affinity 
that is comparable with antibodies and ease of chemical modifications that allowed 
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easy conjugation with a variety of molecules like siRNA/miRNAs, proteins, pep-
tides, antibody, drugs and nanoparticles. However, there have also been challenges 
in the application of aptamers due to their unique characteristics, viz., small size 
that lead to quick renal filtration, serum instability and lack of diversity in aptamer 
library. It is important to note that each of these issues has been addressed in dif-
ferent possible ways. Quick renal filtration of aptamers was tackled by conjugation 
with high molecular weight moieties, e.g., PEG. Similarly, serum instability was 
dealt with introduction of modifications to the nucleic acid backbone and modifica-
tions at 5′- or 3′-end of the oligonucleotide. The diversity of aptamer library was 
increased by introduction of modified bases, and this lead to the development of 
mutant polymerases which were capable of amplifying these unnatural aptam-
ers. Endosomal escape of cell-internalizing aptamers is a very important issue 
that needs to be addressed for clinical translation. Conjugation of aptamer with 
endosome escaping peptides will facilitate this issue. But lysosomal localization of 
aptamers is not always a problem, since lysosomal delivery of proteins or drugs is an 
important aspect of treating lysosomal storage diseases.
Efforts to up the speed of aptamer selection for industrializing this technology 
were achieved by development of high-throughput SELEX, and CE-SELEX which 
brought down the duration of selection process from months or weeks to just a 
few days. Additionally, the development of next-generation sequencing platform 
has been a boon for aptamer selection since it allowed assay of millions of aptamer 
sequences at one go, and alleviated the need to perform several rounds of selection 
that was earlier a norm. It significantly reduced the amount of time and resources 
that went in the selection of aptamers. From the point of selectionologists, it is quite 
important to characterize aptamers in the best possible way, i.e., keep right controls 
and perform vigorous validation experiments to make sure that aptamers coming 
out of a lab are robust, and work in hands of different people. Development of 
working reliable aptamers will pave their way for targeted delivery of therapeutics.
Macugen was the first FDA approved aptamer drug that appeared in market 
for clinical use in 2005. No other aptamer drug has entered the market since then. 
Several aptamers underwent clinical trials in the last 2 decades as listed in earlier 
reviews [5, 97, 98]. However, many of them have failed [5, 98]. In many cases, the 
failure in clinical trials is not due to lack of aptamer specificity or affinity to the 
target, but because they were unable to provide better treatment over the existing 
state-of-the-art treatment regimens. However, it is a common phenomenon that 
more drugs fail during clinical trails than pass it. In the past 2 decades the advances 
described in this chapter have facilitated in the development of stabilized aptam-
ers that have entered clinical trials. In future, application of aptamers in targeted 
delivery and therapeutics is only poised to increase due to the establishment of 
ancillary technologies that facilitate faster and more stable aptamer development. 
Due to this, a number of aptamers are entering clinical trials. In summary, aptamer-
mediated targeted delivery remains a work in progress; however, with bright results 
at in vivo level and several aptamer drugs in clinical trials, the coming decade will 
determine their efficiency at the clinical level.
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